Marpai Inc. reported its third quarter 2025 results, highlighting a $0.10 increase in earnings per share. The company achieved a 24% reduction in operating expenses and a 9% improvement in operating loss compared to the prior year. Marpai also raised $3.9 million through a Private Investment in Public Equity $(PIPE)$ transaction to support its turnaround strategy. The company reported robust sales momentum with more than double-digit new client contracts for January 2026, and continued growth of its integrated MarpaiRx PBM offering. Marpai expects to achieve profitability in the first quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marpai Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-109369), on November 12, 2025, and is solely responsible for the information contained therein.